Chemistry:Pelubiprofen

From HandWiki

Pelubiprofen is a nonsteroidal anti-inflammatory drug of the profen class used to treat back pain and osteoarthritis.[1]

Pelubiprofen was developed in South Korea by Daewon Pharmaceuticals and it is marketed in Korea and Russia,[2] among other countries.

Research

Pelubiprofen is being studied for use in combination with eperisone.[3]

Because pelubiprofen has low water solubility, development of salt formulations with better solubility are being studied.[4]

Synthesis

Pelubiprofen can be prepared by the reaction of 1-(1-piperidino)cyclohexene (1) with ethyl 2-(4-formylphenyl)propanoate (2).[5][6][7][8][9][10][11]

Synthesis of pelubiprofen

References

  1. "Pelubiprofen - Daewon Pharmaceutical". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800000947. 
  2. "Daewon Pharm wins $3 million deal to export Pelubi to Indonesia". Korea Biomedial Review. 26 September 2023. https://www.koreabiomed.com/news/articleView.html?idxno=22165. 
  3. "(Eperisone + pelubiprofen) by Daewon Pharmaceutical for Low Back Pain: Likelihood of Approval". 5 June 2023. https://www.pharmaceutical-technology.com/data-insights/pelubiprofen-sr-daewon-pharmaceutical-chronic-low-back-pain-clbp-likelihood-of-approval/?cf-view. 
  4. "Development of Pelubiprofen Tromethamine with Improved Gastrointestinal Safety and Absorption". Pharmaceutics 13 (5): 745. May 2021. doi:10.3390/pharmaceutics13050745. PMID 34070062. 
  5. Serradell, MN; Castaer, J.; RS-2131. Drugs Fut 1984, 9, 4, 275.
  6. Terada, Atsusuke; Naruto, Shunji; Wachi, Kazuyuki; Tanaka, Shigeru; Iizuka, Yoshio; Misaka, Eiichi (1984). "Synthesis and antiinflammatory activity of [(cycloalkylmethyl)phenyl]acetic acids and related compounds". Journal of Medicinal Chemistry. 27 (2): 212–216. doi:10.1021/jm00368a019.
  7. Atsusuke Terada, Shigeru Tanaka, & Eiichi Misaka, US4254274 (1981 to Sankyo Co Ltd).
  8. Yuan Weiguan, et al. CN111153791 (2020 to HUNAN JIUDIAN HONGYANG PHARMACEUTICAL Co., Ltd).
  9. Yuan Weiguan, et al. WO2021129651 (to Hunan Jiudian Pharmaceutical Co Ltd).
  10. Ning Hulin, et al. CN110041191 (2019 to HUNAN JIUDIAN HONGYANG PHARMACEUTICAL Co., Ltd.).
  11. ChemDrug